Search Result

Isoforms Recommended:	IRAK4

Results for "

IRAK4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (9) Autophagy (5) c-Met/HGFR (3) CDK (1) Cyclic GMP-AMP Synthase (1) E3 Ligase Ligand-Linker Conjugates (1) FLT3 (2) IRAK (76) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (4) MAP3K (1) MAP4K (1) MyD88 (3) NF-κB (5) p38 MAPK (1) Pim (1) PROTAC Linkers (1) PROTACs (20) Reactive Oxygen Species (2) Small Interfering RNA (siRNA) (3) TNF Receptor (1) Toll-like Receptor (TLR) (3) Trk Receptor (1)
By Research Areas:	Cancer (56) Infection (3) Inflammation/Immunology (49) Neurological Disease (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

100

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-77048

IRAK-4 protein kinase inhibitor 2	IRAK	Inflammation/Immunology
IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC₅₀ of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders .

HY-109585

IRAK4-IN-7	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .

HY-160654

IRAK4 modulator-1	IRAK	Inflammation/Immunology
IRAK4 modulator-1 (example 161) is a modulator of *IRAK4* with *IC₅₀*=4.647 μM. IRAK4 modulator-1 can be used to study IRAK-mediated disorders .

HY-RS06898

IRAK4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IRAK4 Human Pre-designed siRNA Set A contains three designed siRNAs for IRAK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IRAK4 Human Pre-designed siRNA Set A IRAK4 Human Pre-designed siRNA Set A

HY-RS06899

Irak4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Irak4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Irak4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Irak4 Mouse Pre-designed siRNA Set A Irak4 Mouse Pre-designed siRNA Set A

HY-RS06900

Irak4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Irak4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Irak4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Irak4 Rat Pre-designed siRNA Set A Irak4 Rat Pre-designed siRNA Set A

HY-155132

IRAK4-IN-28	IRAK	Inflammation/Immunology
IRAK4-IN-28 (compound 42) is an orally active *IRAK4* inhibitor (IC₅₀=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases .

HY-155519

IRAK4-IN-26	IRAK	Inflammation/Immunology
IRAK4-IN-26 (Compound 21) is a *IRAK4* inhibitor (IC₅₀: 6.2 nM). IRAK4-IN-26 displays an oral bioavailability of 21%. IRAK4-IN-26 can be used for research of inflammatory and autoimmune disorders .

HY-143486

IRAK4-IN-10	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-10 (compound 75) is a potent *IRAK4* inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-10 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-143485

IRAK4-IN-9	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-9 (compound 73) is a potent *IRAK4* inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-9 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-123882

IRAK4-IN-29	Others	Others
IRAK4-IN-29 is an IRAK4 inhibitor with good selectivity and low nanomolar activity. IRAK4-IN-29 can effectively block the TLR-mediated signal transduction pathway. IRAK4-IN-29 showed significant inhibitory effects in LPS- and R848-induced cytokine experiments. IRAK4-IN-29 can inhibit LPS-induced TNFα in an in vivo model, showing a similar phenotype to IRAK4 gene-deficient mice. IRAK4-IN-29 has good medicinal chemical properties, such as microsomal stability and solubility, showing potential clinical application value .

HY-143231

IRAK4-IN-8	IRAK	Infection
IRAK4-IN-8 (VI-177) is a potent *IRAK4* inhibitor .

HY-149345

IRAK4-IN-24	IRAK	Inflammation/Immunology
IRAK4-IN-24 (compound 16) is a potent *IRAK4* inhibitor, with high clearance (Cl) and poor oral bioavailability. IRAK4-IN-24 can be used for research in inflammatory and autoimmune disorders.

HY-150594

IRAK4-IN-17	IRAK NF-κB	Cancer
IRAK4-IN-17 (Compound 5) is a potent *IRAK4* inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

HY-146072

IRAK4-IN-11	IRAK	Cancer
IRAK4-IN-11 (compound 6) is a potent *IRAK4* inhibitor with an IC₅₀ of 0.008 µM. IRAK4-IN-11 shows cell pIRAK4 potencies with an IC₅₀ of 0.19 µM .

HY-146073

IRAK4-IN-12	IRAK	Cancer
IRAK4-IN-12 (compound 37) is a potent *IRAK4* inhibitor with an IC₅₀ of 0.015 µM. IRAK4-IN-12 shows cell pIRAK4 potencies with an IC₅₀ of 0.5 µM .

HY-150735

IRAK4-IN-20	IRAK	Inflammation/Immunology
IRAK4-IN-20 (Compound BAY-1834845) is an orally active *IRAK4* inhibitor with an IC₅₀ of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .

HY-155574

IRAK4-IN-27	IRAK Apoptosis	Cancer
IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of *IRAK4, with IC₅₀* of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study .

HY-150732

IRAK4-IN-18	IRAK	Inflammation/Immunology
IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease .

HY-150733

IRAK4-IN-19	IRAK	Inflammation/Immunology
IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease .

HY-146111

IRAK4-IN-13	IRAK	Cancer
IRAK4-IN-13 (compound 21) is a potent and selective *IRAK4* inhibitor with an IC₅₀ of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg .

HY-101922

IRAK4-IN-1	IRAK	Inflammation/Immunology
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-146112

IRAK4-IN-14	IRAK	Cancer
IRAK4-IN-14 (compound 28) is a potent, selective and orally active *IRAK4* inhibitor with an IC₅₀ of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib .

HY-155518

IRAK4-IN-25	IRAK	Inflammation/Immunology
IRAK4-IN-25 (compound 38) is an orally acitve and potent IRAK4 inhibitor (IC₅₀=7.3 nM), with low clearance (Cl=12 mL/min/kg). IRAK4-IN-25 inhibits production of pro-inflammatory cytokines, and shows in vitro safety and ADME profiles. IRAK4-IN-25 can be used for research in inflammatory and autoimmune disorders .

HY-146113

IRAK4-IN-15	IRAK	Cancer
IRAK4-IN-15 (compound 35) is a potent and selective *IRAK4* inhibitor with an IC₅₀ of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .

HY-151363

IRAK4-IN-21	IRAK	Inflammation/Immunology
IRAK4-IN-21 (compound 17) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 5 and 56 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-151365

IRAK4-IN-22	IRAK	Inflammation/Immunology
IRAK4-IN-22 (compound 18) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 3 and 17 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-114181

IRAK4-IN-4 1 Publications Verification	IRAK Cyclic GMP-AMP Synthase	Inflammation/Immunology
IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC₅₀ of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC₅₀ of 2.1 nM .

HY-130253

IRAK4-IN-6	IRAK	Cancer
IRAK4-IN-6 is an orally efficacious and selective *IRAK4* inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma .

HY-150593

IRAK4-IN-16	IRAK	Cancer
IRAK4-IN-16 (compound 4) is a potent *IRAK4* (interleukin-1 receptor associated kinase 4) inhibitor, with an IC₅₀ of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC₅₀ values of 0.2, 0.2, 0.6, and 2.7 μM, respectively .

HY-135382

*PROTAC IRAK4* degrader-2**	PROTACs IRAK	Inflammation/Immunology Cancer
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC₅₀ in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC₅₀ of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .

HY-139316

*PROTAC IRAK4* degrader-5**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-5 is a Cereblon-based *IRAK4* degrader extracted from patent US20190192668A1, compound I-171 .

HY-168586

*PROTAC IRAK4* degrader-12**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-12 is a PROTAC based on Cereblon ligand, inducing a maximum degradation rate of IRAK4 of 108.46% in K562 cells with an IC₅₀ value of 4.87 nM ( Structure Note: Pink, IRAK4 inhibitor (HY-168611); Blue, E3 (HY-W733885); Black, linker (HY-168613)) .

HY-168611

*PROTAC IRAK4* ligand-4**	Ligands for Target Protein for PROTAC IRAK	Cancer
PROTAC IRAK4 ligand-4 is a Ligand for Target Protein for PROTAC with antitumor activity. PROTAC IRAK4 ligand-4 can be used to synthesize PROTAC IRAK4 degrader-12 (HY-168586) .

HY-153673

*PROTAC IRAK4* degrader-8**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC *IRAK4* degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively .

HY-129966

*PROTAC IRAK4* degrader-1** 1 Publications Verification	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively .

HY-129967

*PROTAC IRAK4* ligand-1**	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-135382A

*PROTAC IRAK4* degrader-3**	IRAK PROTACs	Inflammation/Immunology
PROTAC IRAK4 degrader-3 is a PROTAC-induced *IRAK4* degrader based on von Hippel-Lindau .

HY-158758

*PROTAC IRAK4* degrader-10**	PROTACs IRAK	Inflammation/Immunology
PROTAC IRAK4 degrader-10 (compound 10) is an oral active PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 95.94% and the DC₅₀ of 7.68 nM in HEK293 cells (Sturcture Note:(Blue: Cereblon ligand, Black: linker；Pink: IRAK4 ligand) .

HY-158760

*PROTAC IRAK4* degrader-11**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-11 (compound 15) is PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 96.25% and the DC₅₀ of 2.29 nM in HEK293 cells(Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker；Pink: IRAK4 inhibitor) .

HY-139315

*PROTAC IRAK4* degrader-4**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .

HY-139317

*PROTAC IRAK4* degrader-6**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .

HY-168311

*PROTAC IRAK4* ligand-5**	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-5 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). PROTAC IRAK4 ligand-5 can be utilized for the synthesis of KT-413 (HY-153368).

HY-145484

*PROTAC IRAK4* ligand-3**	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-3 is a ligand of PROTAC KT-474 (HY-145483) that can be used in cancer research .

HY-145483

KT-474 KYM-001; PROTAC IRAK4 degrader-7	PROTACs IRAK Apoptosis	Cancer
KT-474 (KYM-001) is an orally active PROTAC IRAK4 degrader with antitumor activities . KT-474 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148275

KTX-955	PROTACs IRAK	Cancer
KTX-955 is an antumor and effective *IRAK4* degrader, with DC₅₀ values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively . KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735).

HY-123956

HG-12-6	IRAK	Inflammation/Immunology
HG-12-6 is a type II inhibitor of *IRAK4. HG-12-6 shows preferential binding to unphosphorylated inactive IRAK4* with an IC₅₀ of 165 nM. HG-12-6 can modulate *IRAK4* activity in autoimmunity and inflammation .

HY-W087383

Thalidomide 5-fluoride	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 5-fluoride is Thalidomide-based cereblon ligand that incorporates to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.

HY-148274

KTX-582	PROTACs IRAK Apoptosis	Cancer
KTX-582 is a potent *IRAK4* degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88 ^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model .

HY-148276

KTX-497	PROTACs IRAK	Cancer
KTX-497 is an *IRAK4* PROTAC degrader with a DC₅₀ value of 3 nM. KTX-497 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

Cat. No.	Product Name	Target	Research Area

HY-P5432

IRAK-4 Peptide substrate IRAK-1 (360-380)	Peptides	Others
IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. (This is a substrate peptide for Interleukin-1 Receptor-Associated Kinase (IRAK) 4)

Species:	Human (2) Mouse (1)
Tag:	His (3)
Source:	Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73255

	IRAK4 Protein, Human (sf9, His) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	Sf9 insect cells
	IRAK4 Protein, a serine/threonine-protein kinase, is pivotal in initiating innate immune responses via Toll-like receptor (TLR) and IL-1R signaling pathways. Upon TLR activation, it rapidly forms the Myddosome with IRAK2. IRAK4 phosphorylates IRAK1, promoting its autophosphorylation, and phosphorylates Pellino proteins to facilitate IRAK1 polyubiquitination. This leads to NF-kappa-B activation and regulates immune responses during microbial infections. Additionally, it phosphorylates TIRAP, influencing its ubiquitination and degradation. IRAK4 Protein, Human (sf9, His) is the recombinant human-derived IRAK4 protein, expressed by Sf9 insect cells , with N-10*His labeled tag. The total length of IRAK4 Protein, Human (sf9, His) is 460 a.a., with molecular weight of ~48 kDa.

HY-P703078

	IRAK4 Protein, Mouse (His) Interleukin-1 receptor-associated kinase 4; IRAK-4; EC:2.7.11.1	Mouse	E. coli
	IRAK4 Protein, Mouse (His) is the recombinant mouse-derived IRAK4, expressed by E. coli , with N-6*His labeled tag. ,

HY-P702732

	IRAK4 Protein, Human (307a.a, sf9, His) Interleukin-1 receptor-associated kinase 4; IPD1; IRAK4; NY-REN-64; REN64	Human	Sf9 insect cells
	The IRAK4 protein is a serine/threonine protein kinase that is critical for initiating the innate immune response through the Toll-like receptor (TLR) and IL-1R signaling pathways. After TLR is activated, it rapidly forms the Myddosome with IRAK2. IRAK4 Protein, Human (307a.a, sf9, His) is the recombinant human-derived IRAK4, expressed by Sf9 insect cells , with His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83370

	IRAK4 Antibody (YA3115) IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; IPD1; IRAK4; LOC 51135; NY REN 64; REN64	WB, IHC-F, IHC-P, ICC/IF	Human
	IRAK4 Antibody (YA3115) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3115), targeting IRAK4, with a predicted molecular weight of 52 kDa (observed band size: 52 kDa). IRAK4 Antibody (YA3115) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: